

RESEARCH

Open Access



Granulocyte macrophage colony-stimulating factor-induced macrophages of individuals with autism spectrum disorder adversely affect neuronal dendrites through the secretion of pro-inflammatory cytokines

Ryohei Takada¹, Michihiro Toritsuka^{1*}, Takahira Yamauchi¹, Rio Ishida¹, Yoshinori Kayashima¹, Yuki Nishi¹, Mitsuru Ishikawa², Kazuhiko Yamamuro¹, Minobu Ikehara¹, Takashi Komori¹, Yuki Noriyama¹, Kohei Kamikawa¹, Yasuhiko Saito³, Hideyuki Okano² and Manabu Makinodan^{1,4}

Abstract

Background A growing body of evidence suggests that immune dysfunction and inflammation in the peripheral tissues as well as the central nervous system are associated with the neurodevelopmental deficits observed in autism spectrum disorder (ASD). Elevated expression of pro-inflammatory cytokines in the plasma, serum, and peripheral blood mononuclear cells of ASD has been reported. These cytokine expression levels are associated with the severity of behavioral impairments and symptoms in ASD. In a prior study, our group reported that tumor necrosis factor- α (TNF- α) expression in granulocyte-macrophage colony-stimulating factor-induced macrophages (GM-CSF M Φ) and the TNF- α expression ratio in GM-CSF M Φ /M-CSF M Φ (macrophage colony-stimulating factor-induced macrophages) was markedly higher in individuals with ASD than in typically developed (TD) individuals. However, the mechanisms of how the macrophages and the highly expressed cytokines affect neurons remain to be addressed.

Methods To elucidate the effect of macrophages on human neurons, we used a co-culture system of control human-induced pluripotent stem cell-derived neurons and differentiated macrophages obtained from the peripheral blood mononuclear cells of five TD individuals and five individuals with ASD. All participants were male and ethnically Japanese.

Results Our results of co-culture experiments showed that GM-CSF M Φ affect the dendritic outgrowth of neurons through the secretion of pro-inflammatory cytokines, interleukin-1 α and TNF- α . Macrophages derived from individuals with ASD exerted more severe effects than those derived from TD individuals.

Limitations The main limitations of our study were the small sample size with a gender bias toward males, the use of artificially polarized macrophages, and the inability to directly observe the interaction between neurons and macrophages from the same individuals.

*Correspondence:

Michihiro Toritsuka

tori-m@naramed-u.ac.jp

Full list of author information is available at the end of the article



© The Author(s) 2024. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Conclusions Our co-culture system revealed the non-cell autonomous adverse effects of GM-CSF M Φ in individuals with ASD on neurons, mediated by interleukin-1 α and TNF- α . These results may support the immune dysfunction hypothesis of ASD, providing new insights into its pathology.

Keywords Autism spectrum disorder, Human iPSC cell, Macrophage, Interleukin-1 α , Tumor necrosis factor- α , Dendrite

Background

Autism spectrum disorder (ASD) is a complex neurodevelopmental disorder characterized by impaired social interaction, poor communication skills, and restricted or repetitive patterns of behavior and interests [1]. The worldwide prevalence of autism has steadily increased in recent decades, which is still about 1% [2, 3]. Although its etiology and pathogenesis have not been fully elucidated, a growing body of evidence suggests that immune dysfunction and inflammation are associated with the neurodevelopmental deficits observed in ASD [4–7]. For example, a significant association between common allergic conditions (food, respiratory, or skin allergy) and autoimmune diseases in ASD has been reported [8, 9], suggesting that there are systemic abnormalities of the immune system both in the periphery and in the central nervous system (CNS) of patients with ASD. Postmortem studies have revealed the existence of neuroinflammation in the CNS, as indicated by the expression of the genes of immune-related signaling pathways, microglial activation, and upregulation and mutation of microglia-related genes in the brains of patients with ASD [10–12]. In the periphery, pro-inflammatory cytokines were elevated in the plasma, serum, and peripheral blood mononuclear cells (PBMCs) of individuals with ASD, which was associated with the severity of behavioral impairments and associated with symptoms in children with ASD [13, 14]. Epigenetic changes in hematopoietic cells during embryogenesis reportedly alter definitive hematopoiesis and microglial development, leading to such immune abnormalities [15].

It has been believed that the CNS is protected from the periphery by the blood–brain barrier (BBB). Depending on their type, cytokines can pass through the BBB [16], whereas peripheral immune cells face challenges in accessing the brain; however, recent reports have shown that the integrity of the BBB may be disrupted by the systemic inflammation observed in ASD [17, 18]. In addition, even without disruptive BBB changes, peripheral cytokines and peripheral immune cells, such as monocytes and macrophages, can be secreted or activated by social stress and systemic inflammation. These cytokines and immune cells may cause the activation of endothelial cells and perivascular macrophages, which release secondary messengers to affect the brain [19–22].

Macrophages are diverse, highly plastic, mononuclear phagocytic cells with a functional similarity to microglia, which play critical roles in CNS health and disease. Although the origin of macrophages, especially monocyte-derived intravascular macrophages, is known to be different from microglia [23], microglia are nevertheless considered tissue-resident macrophages. Additionally, a recent report identified another type of macrophage associated with the CNS, which is distinct from both microglia and intravascular macrophages, named CNS-associated macrophages (CAMs) [24]. CAMs can be divided into two types of cells; one of these, termed perivascular macrophages, settles in the perivascular space in the brain soon after birth and has the potential to interact with intravascular macrophages. This interaction with macrophages could affect brain cells, including microglia and neurons [24].

Microglia and macrophages exhibit a spectrum of phenotypes [25, 26]. We have reported that the expression of tumor necrosis factor- α (TNF- α), a pro-inflammatory cytokine, in granulocyte–macrophage colony-stimulating factor-induced macrophages (GM-CSF M Φ ; classic nomenclature “M1 M Φ ”), and the TNF- α expression ratio in GM-CSF M Φ /M-CSF M Φ (macrophage colony-stimulating factor-induced macrophages; classic nomenclature “M2 M Φ ”) are markedly higher in individuals with ASD than in typically developed (TD) individuals [27]. Therefore, we focused our investigation on how peripheral macrophages affect brain cells in individuals with ASD. In rodent models, repeated environmental stress induces the activation of microglia in the medial prefrontal cortex (mPFC) to express pro-inflammatory cytokines such as interleukin-1 α (IL-1 α) and TNF- α , which leads to the shortening of and reduced branching of neural dendrites and leads to social avoidance behavior [28, 29]. This mechanism appears relevant to ASD, as those with autistic traits are prone to stress and anxiety, resulting in a higher prevalence of social withdrawal [30, 31]. We previously reported that impaired social interaction during childhood is related to elevated blood levels of TNF- α in individuals with ASD [32]; thus, the highly expressed pro-inflammatory cytokines in macrophages of individuals with ASD [27] may have a similar effect on brain morphology and behavior.

Herein, we hypothesized that macrophages in individuals with ASD would affect neuronal cells differentially

from that of TD individuals due to their inflammatory phenotype. To investigate this hypothesis, we co-cultured human-induced pluripotent stem cell (hiPSC)-derived neurons with differentiated GM-CSF M Φ or M-CSF M Φ from TD individuals and individuals with ASD. We examined how macrophages cause morphological changes in neurons.

Methods

Participants and clinical assessments

Five individuals with ASD (age: 31.0 ± 7.25 years) and five TD individuals (age: 34.8 ± 7.60 years) of Japanese ethnicity were enrolled. All participants were male and born and living in Japan. The participation criteria and assessment of clinical features were the same as those described previously [27]. Briefly, individuals with ASD were recruited from the outpatient service of the Department of Psychiatry at Nara Medical University Hospital. ASD diagnosis was based on the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition criteria. At least two experienced psychiatrists examined each individual separately, and a diagnostic consensus was reached. Further evaluation was performed using the Autism Diagnostic Observation Schedule-2 (ADOS-2) by psychiatrists and trained staff [33]. Autism symptom severity was assessed via self-reporting using the Autism Quotient-Japanese version (AQ-J) [34, 35]. All participants had average intelligence higher than the full intelligence quotient (FIQ) of 70, estimated using the Similarities and Symbol search subtests of the Wechsler Adult Intelligence Scale, 3rd ed. [36]. Participants had no other neurological disorders, mental illnesses, infectious diseases, autoimmune diseases, or steroid use. This study was approved by the appropriate ethics committees of Nara Medical University and was conducted as per the Code of Ethics of the World Medical Association (Declaration of Helsinki) for experiments involving humans. All participants were given a complete description of the study and provided written informed consent before enrollment.

Neuronal differentiation of hiPSCs

Two human iPSC lines, 201B7 [37] and 1008C15, were used as healthy control hiPSC lines. The 1008C15 line was established from human dermal fibroblasts of a TD male based on a previously described method in our laboratory [38]. Human iPSCs were cultured in StemFit AK02N (Ajinomoto, Tokyo, Japan), plated onto a 35 mm culture dish coated with iMatrix-511 silk (Nippi, Tokyo, Japan) without feeder cells at 37 °C in humidified air containing 5% CO₂.

Neuronal differentiation was performed according to the previously described method [39]. Briefly,

the following plasmid vectors were used to establish *NEUROG2*-inducible hiPSCs: PB-TET-PH-lox66FRT-*NEUROG2*, pCMV-HyPBase-PGK-Puro, and PB-CAGrtTA3G-IH. These vectors were co-transfected into hiPSCs using Gene Juice Transfection Reagent (Novagen, Madison, Wisconsin, USA). Transfectants were cultured in StemFit AK02N containing 150 μ g/ml hygromycin (Wako Pure Chemical Industries, Ltd., Osaka, Japan) and 0.1–1.0 μ g/ml puromycin (Sigma-Aldrich, St. Louis, MO, USA). To induce glutamatergic neurons, these *NEUROG2*-inducible hiPSCs were dissociated and seeded on poly-ornithine (Sigma-Aldrich) and iMatrix-511 silk-coated coverslips in 24-well plates at 5×10^4 cells/well, and cultured in neural induction medium; Neurobasal Plus medium supplemented with B-27, 1 \times Glutamax (Invitrogen, Thermo Fisher Scientific Inc., Waltham, MA, USA), 20 μ M Y-27632 (Wako Pure Chemical Industries, Ltd.), 20 μ M DAPT (Sigma-Aldrich), 100 μ g/ml G418 (Nacalai Tesque, Kyoto, Japan), and 1 μ g/ml doxycycline (Wako Pure Chemical Industries, Ltd.). After five days, the medium was replaced with neuron culture medium: Neurobasal Plus medium supplemented with B-27, 1 \times Glutamax, 10 ng/ml brain-derived neurotrophic factor (BDNF; R&D Systems, Minneapolis, MN, USA), 10 ng/ml glial cell line-derived neurotrophic factor (GDNF; Alomone-Labs, Jerusalem, Israel), 200 μ M L-ascorbic acid (Sigma-Aldrich), 200 μ M dibutylryl cyclic adenosine monophosphate sodium salt (Nacalai Tesque), 10 ng/ml neurotrophin-3 (Alomone-Labs), 1 \times Culture-One Supplement (GIBCO, Thermo Fisher Scientific Inc.), and 1% penicillin–streptomycin mixed solution (Nacalai Tesque). The medium was half-replaced twice a week for up to 56 days.

Monocyte isolation and macrophage differentiation

Monocyte isolation was performed with a magnetic-activated cell sorting system (Miltenyi Biotec, Bergisch Gladbach, Germany) and CellXVivo Human M1 or M2 Macrophage Differentiation Kit (R&D Systems), according to the manufacturer's protocol. Briefly, whole human blood samples were collected via venipuncture, and PBMCs were separated by density-gradient centrifugation using the separation medium, Lymphoprep (Axis Shield, Oslo, Norway), and separation tubes, Leucosep (Greiner Bio-One, Kremsmünster, Austria). CD14+ monocytes were isolated from PBMCs using a magnetic-activated cell sorting system with CD14 microbeads (Miltenyi Biotec). For macrophage differentiation, CD14+ monocytes were resuspended in a phosphate-buffered saline solution (PBS) (Wako Pure Chemical Industries, Ltd) containing 0.5% bovine serum albumin (Sigma-Aldrich), 2 mM ethylenediaminetetraacetic acid, and 1% penicillin–streptomycin mixed solution (Nacalai

Tesque). Cells were seeded on 12-well plates coated with poly-L-lysine (IWAKI, Shizuoka, Japan) at a density of 1×10^6 cells/ml and cultured in differentiation medium containing recombinant human granulocyte-macrophage colony-stimulating factor or recombinant human macrophage colony-stimulating factor, at 37 °C in humidified air containing 5% CO₂. On day 3, half of the culture medium was replaced with fresh medium, and GM-CSF M Φ or M-CSF M Φ were collected on day 6 using a cell scraper for co-culture with neurons and subsequent analysis. Some collected macrophages were seeded in 24-well plates coated with poly-L-lysine at a density of 5×10^5 cells/well and cultured in neuron culture medium for up to 28 days for quantitative reverse transcription-polymerase chain reaction (qRT-PCR) analysis. Macrophage differentiation for participants 1–3 in the TD group and 1–3 in the ASD group was performed twice, and only once for participants 4 and 5 of both groups.

Co-culture of neurons and macrophages

Glutamatergic neurons prepared as described above were used on day in vitro 28 (DIV28). For a direct co-culture, differentiated macrophages were collected and reseeded on cultured neurons in a neuron culture medium at a density of 5×10^4 cells/well. For indirect co-culture, macrophages were reseeded on a culture insert (Falcon, NY, USA) coated with iMatrix-511 silk at 5×10^4 cells per insert in neuron culture medium, and the macrophage-containing culture inserts were suspended in 24-well plates. The medium was half-replaced twice per week for an additional 28 days. For each macrophage differentiation, one differentiation of hiPSC-derived neurons was performed; TDs and ASDs were collected in pairs to minimize errors due to neuronal differentiation.

Addition of cytokines and neutralizing antibodies

To examine the cytokine effect, the neuron culture medium was replaced with either or both recombinant human TNF- α and IL-1 α proteins (Peprotech, Cranbury, NJ, USA) at a concentration of 10–100 ng/ml at DIV28. The cytokine-containing medium was half-replaced twice a week for an additional 28 days.

For the neutralizing antibody administration experiment, the neuron culture medium was replaced with either or both neutralizing antibodies of anti-human TNF- α (BioLegend, San Diego, CA, USA) and anti-human IL-1 α (InvivoGen, San Diego, CA, USA) at a concentration of 1 μ g/ml at the start of macrophage co-culture. For the negative control, either or both antibodies were replaced with the same amount of corresponding IgG isotype antibodies. The antibody-containing medium was half-replaced twice a week for an additional 28 days.

Immunocytochemistry (ICC)

Cells were fixed in PBS containing 4% paraformaldehyde for 30 min at room temperature, and then rinsed twice with PBS. Thereafter, cells were blocked and permeabilized for 1 h in blocking buffer (PBS containing 5% donkey- or goat-serum albumin and 0.3% Triton-X) and incubated with the primary antibodies diluted in blocking buffer at 4 °C overnight. After washing thrice with PBS, cells were incubated with Alexa Fluor 488-, 546-, or 633-conjugated secondary antibodies (Invitrogen) at room temperature for 1 h. Nuclei were stained using 4'-diamidino-2-phenyl-indole, dihydrochloride (DAPI; Invitrogen) in PBS, rinsing the cells after incubation with secondary antibodies.

Images were randomly acquired using a Nikon C2 confocal laser microscope with the NIS-Elements AR software (Nikon, Tokyo, Japan). For dendrite analysis, two to three images were collected from each coverslip, and images were randomly acquired across fields using a 20 \times objective lens. Images were taken as z-stack images with a 1 μ m interval for five stacks. Merged images of the stacks were used for analysis. Microtubule-associated protein 2 (MAP2)-positive cells were identified for each image, and the length of MAP2-positive dendrites extending from the cell body was measured. MAP2-positive dendrites were traced and measured manually in a blinded fashion by one researcher using the NIH Image J software. The average, total, and most extended dendrite lengths and total branch numbers of dendrites were quantified (Additional file 1: Fig. S1A). Overlapping dendrites were distinguished from which cell they were from upon reviewing the unmerged z-stack images. Cells with MAP2-positive dendrites that did not fit in the image were excluded from the analysis. Each parameter of MAP2-positive cells was averaged for each image to create a single data point. The number of MAP2-positive cells was calculated by counting the number of both MAP2 and DAPI immunopositive cells in the image.

Statistical analysis

Differences in demographic characteristics (age, AQ-J score, and FIQ) between individuals with ASD and TD individuals were examined using an unpaired t test. Comparisons of MAP2+ dendrite data were performed by one-way analysis of variance (ANOVA) with post hoc multiple comparison test using Tukey's honest significant test (HSD) or Dunnett's multiple comparison test in the study of cytokine addition compared with the vehicle group. When the standard deviations were shown to be significantly different by Bartlett's test, the Brown-Forsythe ANOVA test and Dunnett's T3 multiple comparison tests were used. When comparing

two groups, an unpaired t test or Welch's t test was used. Data are presented as medians with interquartile ranges.

All statistical analyses were performed using Prism 9 (GraphPad, Inc., La Jolla, CA, USA), and differences were considered significant at $p < 0.05$.

Results

Table 1 presents the participants' demographic data. There were no significant differences in age ($t=0.809$, $p=0.442$) or FIQ score ($t=0.350$, $p=0.735$) between the ASD and TD groups. As expected, individuals with ASD had significantly higher AQ-J scores than TD individuals ($t=5.33$, $p=0.0007$).

Neuronal differentiation of hiPSCs into glutamatergic excitatory neurons and co-culture with macrophages

For neuronal differentiation, we prepared two hiPSC lines from healthy controls (Additional file 1: Fig. S1B). The protocol for the baseline analysis using the co-culture system is shown in Fig. 1A. A previous study [39] showed that hiPSC-derived neurons induced by the same method in this study were almost all glutamatergic excitatory neurons. This was confirmed by examining the expression of beta III tubulin (Tuj-1) and vesicular glutamate transporter 2 (vGlut2) at DIV28 by ICC (Fig. 1B),

Table 1 Demographic data of the study participants

	TD (n=5)	ASD (n=5)	
Age (years)	34.8 (7.60)	31.0 (7.25)	$t=0.809$, $p=0.442$
FIQ	110 (9.14)	108 (12.1)	$t=0.350$, $p=0.735$
AQ-J	14.0 (6.96)	34.2 (4.82)	$t=5.33$, $p=0.0007$

Data presented as mean (SD), and unpaired t test was performed




Fig. 1 Co-culture system of hiPSC-derived neurons and macrophages. **A** Summary of neuronal differentiation of hiPSCs into glutamatergic neurons and the macrophage differentiation and co-culture protocol. **B** Immunocytochemistry at DIV28 to characterize hiPSCs-derived glutamatergic neurons of two hiPS cell lines. Expression of excitatory neuronal marker vesicular glutamate transporter 2 (vGlut2) on neuron-specific class III beta-tubulin (Tuj-1) observed. Scale bar: 30 μm . **C** Immunocytochemistry at DIV30, 2 days after co-culture, and DIV56. Ionized calcium-binding adapter molecular 1 (Iba-1) immunopositive macrophages of TD1 were observed on hiPSC-derived neurons from 201B7 hiPSC line. Scale bar: 100 μm . **D** 3D-reconstitution of the upper image by NIH ImageJ volume viewer shown below. The upper image was reconstructed and rotated 175 degrees on the x-axis, 40 degrees on the y-axis, and 75 degrees on the z-axis. Scale bar: 20 μm

and the absence of glial fibrillary acidic protein (GFAP)-positive astrocytes at DIV56 was also confirmed by ICC (Additional file 1: Fig. S1C). In addition, we evaluated the electrophysiological features of hiPSC-derived neurons using the whole-cell patch-clamp method at DIV28. Action potentials and spontaneous excitatory postsynaptic currents were recorded from both hiPSC line-derived neurons, indicating the neuronal viability and functional connectivity (Additional file 1: Fig. S1D). We further confirmed that ionized calcium-binding adapter molecule 1 (Iba1) immunopositive macrophages were present on neurons using ICC at DIV30, two days after the start of co-culture, and at DIV56 (Fig. 1C and D). The polarization of differentiated macrophages was verified by qRT-PCR at day 6 in macrophage differentiation medium (Additional file 1: Fig. S1E). GM-CSF M Φ showed an inflammatory profile of high expression of *IL-1 α* and low expression of *IL-10*, while M-CSF M Φ showed an anti-inflammatory profile with opposite expression pattern in both TD and ASD groups.

ASD-GM-CSF M Φ induce significantly greater shortening of dendrites than TD-GM-CSF M Φ

To evaluate the effect of macrophages on neurons during co-culture, we investigated the morphology of MAP2 immunopositive dendrites by measuring their length and number. DIV56-neuron showed a more mature phenotype compared to DIV28-neuron with longer dendrite length and many dendritic branches, but the number of dendrites showed no difference (Fig. 2A–F and Additional file 1: Fig. S2A). This result suggests that basic cell morphology, including dendrite projection, is nearly completed by DIV28, with maturation and further branching progressing by DIV56 in this co-culture system. However, GM-CSF M Φ , in both TD and ASD, may inhibit this maturation process. Neurons cultured with GM-CSF M Φ showed shorter lengths and less branches than neurons cultured without GM-CSF M Φ at DIV56,

and this inhibitory effect was severe in ASD-GM-CSF M Φ with a significant difference compared to TD-GM-CSF M Φ (Fig. 2A–F). There was no significant difference in the number of MAP2+neurons between DIV56-neuron and neurons co-cultured with GM-CSF M Φ . Therefore, it is unlikely that these dendritic changes were caused by the death of MAP2 immunopositive neurons (Additional file 1: Fig. S2B). Comparing neurons cultured with GM-CSF M Φ to DIV28-neuron, the dendrite length was significantly shorter in DIV28-neuron (Fig. 2B–D). Still, the number of branch points (Fig. 2F) and the number of dendrites (Fig. 2E) remained the same in all groups. There was no significant difference in MAP2+ dendrites between neurons cultured with M-CSF M Φ , and their length, number, and branch points were comparable to DIV56-neuron (Additional file 1: Fig. S2C–H).

GM-CSF M Φ induce dendritic shortening by humoral factor secretion

We performed a transwell assay to elucidate whether the GM-CSF M Φ -induced dendritic shortening is contact-dependent or not (Fig. 3A). The results were similar to those of the direct-contact co-culture with GM-CSF M Φ , with comparable data except for the number of branches that remained in a significant trend between TD-GM-CSF M Φ and ASD-GM-CSF M Φ (Fig. 3B–G). Therefore, we hypothesized that humoral factors secreted by GM-CSF M Φ affect dendrites. Among such humoral factors, we focused on pro-inflammatory cytokines because, as mentioned above, a previous study reported that both TNF- α and IL-1 α induce dendritic atrophy in mouse models [29], and a human study has also reported that a mixture of inflammatory cytokines (TNF- α , IL-1 β , IL-6, IL-17A, and interferon- γ (IFN- γ)) decrease the neurite outgrowth of human neural precursor cell line-derived neurons [40]. Since IFN- γ has been reported to increase neurite outgrowth in a hiPSC model [41], gene expression of *IFN- γ* was not specific to GM-CSF M Φ from our

(See figure on next page.)

Fig. 2 Dendritic changes induced by GM-CSF M Φ . **A** Representative images of immunostaining of MAP2+ dendrites. All neurons were induced from 201B7 hiPSC line, and neuron only or co-cultured with macrophages of TD2 or ASD3 were used in these images. Scale bar: 100 μ m. **B–F** Results of **(B)** total length of MAP2+ dendrite, **C** average length of MAP2+ dendrite, **D** max length of MAP2+ dendrite, **E** MAP2+ dendrite count, and **F** branch point count of MAP2+ dendrite. Co-culture of GM-CSF M Φ -induced shortening of dendrites compared to culturing only neurons at DIV56, and ASD-GM-CSF M Φ exerted more severe effects than TD-GM-CSF M Φ . **B** Brown–Forsythe ANOVA test, $F(3.00, 78.20) = 107.6$, $p < 0.0001$, with post hoc multiple comparison test of Dunnett's T3. **C** Brown–Forsythe ANOVA test, $F(3.00, 115.5) = 62.56$, $p < 0.0001$, with post hoc multiple comparison test of Dunnett's T3. **D** Brown–Forsythe ANOVA test, $F(3.00, 109.1) = 98.52$, $p < 0.0001$, with post hoc multiple comparison test of Dunnett's T3. **E** One-way ANOVA test, $F(3, 138) = 2.426$, $p = 0.0682$, with post hoc Tukey's multiple comparison test. **F** Brown–Forsythe ANOVA test, $F(3.00, 93.22) = 14.30$, $p < 0.0001$, with post hoc multiple comparison test of Dunnett's T3. n(DIV28-neuron) = 34 fields of 16 independent dishes from five times differentiations of two control healthy hiPSC lines each, n(DIV56-neuron) = 31 fields of 14 independent dishes from five times (201B7) and 4 times (1008C15) differentiations of two control healthy hiPSC lines each, n(TD-GM-CSF M Φ) = 39 fields of 19 independent dishes from five times differentiations of two control healthy hiPSC lines each, and n(ASD-GM-CSF M Φ) = 38 fields of 18 independent dishes from five times differentiations of two control healthy hiPSC lines each. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$, **** $p < 0.0001$




Fig. 2 (See legend on previous page.)




Fig. 3 Transwell assay of GM-CSF MΦ. **A** Summary of the transwell assay. **B** Representative images of immunostaining of MAP2 + dendrite cultured with TD- or ASD-GM-CSF MΦ indirectly at DIV56. All neurons were induced from 201B7 hiPSC line, and co-cultured with macrophages of TD3 or ASD1 were used in these images. Scale bar: 100 μm. **C–G** Results of **(C)** total length of MAP2+ dendrite, **D** average length of MAP2+ dendrite, **E** max length of MAP2+ dendrite, **F** MAP2+ dendrite count, and **G** branch point count of MAP2+ dendrite. Similar dendritic shortening to the results of direct co-culture was observed in transwell assay. **C** Unpaired t test, $t = 3.592$, $p = 0.0006$. **D** Welch's t test, $t = 2.010$, $p = 0.0484$. **E** Unpaired t test, $t = 2.956$, $p = 0.0041$. **F** Unpaired t test, $t = 1.757$, $p = 0.0830$. **G** Unpaired t test, $t = 1.960$, $p = 0.0536$. $n(\text{TD-GM-CSF M}\Phi \text{ transwell}) = 39$ fields of 19 independent dishes from five times differentiations of two control healthy hiPSC lines each, and $n(\text{ASD-GM-CSF M}\Phi \text{ transwell}) = 40$ fields of 20 independent dishes from five times differentiations of two control healthy hiPSC lines each. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$

qRT-PCR analysis (Additional file 1: Fig. S1E), and we reported higher gene expression of *TNF- α* and no difference in *IL-6* and *IL-17RA* expression in GM-CSF M Φ of individuals with ASD in our previous study [27], and we focused on *TNF- α* and *IL-1 α* in this study. However, our previous data were obtained from macrophages soon after differentiation from PBMCs for 6 days in macrophage differentiation medium; thus, we analyzed the gene expression of GM-CSF M Φ after 28 days of culture in neuron medium to mimic the co-culture condition (Additional file 1: Fig. S3A). Quantitative RT-PCR analysis showed a higher expression of *IL-1 α* in ASD-GM-CSF M Φ than in TD-GM-CSF M Φ , but the expression level of *TNF- α* showed only a tendency to increase, which is consistent with the trend from the results of a previous study (Additional file 1: Fig. S3B and C).

Pro-inflammatory cytokines have the potential to shorten the dendrites of hiPSC-derived excitatory neurons

Next, we added these cytokines to the neuron culture medium to ascertain the direct effect of cytokines on MAP2+ dendrites. Although no significant difference in *TNF- α* expression was observed between ASD-GM-CSF M Φ and TD-GM-CSF M Φ on qRT-PCR analysis after neuron medium culture, we considered it hasty to conclude that one is more important than the other based solely on this qRT-PCR result as *TNF- α* and *IL-1 α* are known to interact and induce each other's expression with further additive effects [42]; thus, we used both cytokines in the addition experiment (Fig. 4A). The expression of each receptor in our hiPSC-derived neurons was confirmed by ICC and qRT-PCR (Additional file 1: Fig. S4). Neurons cultured with these cytokines had shorter dendrites (Fig. 4B–E). Furthermore, this effect was stronger when both were added than when only one was added. The number of dendrites was still the same in all groups (Fig. 4F). Still, the results for the number of branches were not as consistent as when co-cultured with macrophages, with no difference between groups, except for the addition of *TNF- α* at higher concentrations (Fig. 4G). These results confirmed that cytokines affect dendrites.

Administration of neutralizing antibodies against *TNF- α* and *IL-1 α* prevented dendritic shortening induced by GM-CSF M Φ

To confirm that cytokines released from GM-CSF M Φ induce dendritic shortening and to explore the rescue possibility of neutralizing antibodies, we administered neutralizing antibodies against *TNF- α* and *IL-1 α* for 28 days in neuron culture medium (Fig. 5A). We conducted preliminary experiments with the TD-GM-CSF M Φ of three individuals at antibody concentrations of

100 ng/ml and 1 μ g/ml and obtained no rescue effect at the antibody concentration of 100 ng/ml (Additional file 1: Fig. S5). Simultaneous administration of neutralizing antibodies at the antibody concentration of 1 μ g/ml prevented the shortening of MAP2+ dendrites in co-culture with TD-GM-CSF M Φ (Fig. 5B–G) and ASD-GM-CSF M Φ (Fig. 6A–F). The respective neutralizing antibodies exerted a preventive effect to some extent. Still, simultaneous administration of both antibodies was more effective, especially in co-culture with ASD-GM-CSF M Φ , with a significant prevention effect compared to the two antibodies observed in total length and a maximum length of dendrites and branch points (Fig. 6B, D, and F).

Discussion

In the present study, we showed that human GM-CSF M Φ affect human neurons by inhibiting the outgrowth of MAP2+ dendrites in our co-culture system of hiPSC-derived neurons and macrophages differentiated from peripheral blood monocytes, and that this inhibitory effect is more severe in the GM-CSF M Φ of individuals with ASD than that in TD individuals. In addition, we concluded that two pro-inflammatory cytokines, *TNF- α* and *IL-1 α* , secreted by GM-CSF M Φ , play a crucial role in this phenomenon. A previous study in a rodent model showed that *TNF- α* and *IL-1 α* secreted from activated microglia in the mPFC lead to the shortening of dendrite length and reduction of dendrite branches [29]. However, to the best of our knowledge, our results are the first to show this relationship in human cells. In this aforementioned rodent model, microglial activation was induced by repeated social defeat stress, and the neuronal damage caused by secreted cytokines led to social avoidant behavior as a result [29]. Taken together with our results that GM-CSF M Φ of individuals with ASD had more severe effects, a similar mechanism could cause the vulnerability to social stress and a tendency for social withdrawal to be observed in individuals with ASD [30, 31]. Additionally, the hiPSC-derived neurons we used in this study were still in the process of maturation from DIV28 to DIV56, in which period macrophages were co-cultured. Thus, the observed macrophage effects on neurons suggest that immune abnormalities underlie autism pathology from the brain developmental stage and may lead to changes as indicated by increased short-range projection and decreased long-range projection in human imaging study [43]. Reduced MAP2 expression was reported in the prefrontal cortex of two individuals with ASD in postmortem brain case reports [44]. Furthermore, neurons derived from the iPSCs of individuals with 16p11.2 duplication syndrome, a known genetic risk factor for ASD, have shortened dendrites and reduced




Fig. 4 Effects of pro-inflammatory cytokines on neuronal dendrites. **A** Summary of the cytokine addition assay. **B** Representative images of immunostaining of MAP2 + dendrites cultured with TNF- α , IL-1 α , or both at DIV56. All neurons induced from 201B7 hiPSC line used in these images. Scale bar: 100 μm . **C–G** Results of **(C)** total length of MAP2 + dendrite, **D** average length of MAP2 + dendrite, **E** max length of MAP2 + dendrite, **F** MAP2 + dendrite count, and **G** branch point count of MAP2 + dendrite. Addition of pro-inflammatory cytokines in the culture medium-induced shortening of the total length of MAP2 + dendrites in a manner similar to co-culture with GM-CSF M Φ . **C** One-way ANOVA test, $F(6, 50) = 8.107$, $p < 0.0001$, with post hoc Dunnett’s multiple comparison test. **D** One-way ANOVA test, $F(6, 50) = 6.918$, $p < 0.0001$, with post hoc Dunnett’s multiple comparison test. **E** One-way ANOVA test, $F(6, 50) = 9.996$, $p < 0.0001$, with post hoc Dunnett’s multiple comparison test. **F** One-way ANOVA test, $F(6, 50) = 2.061$, $p = 0.0746$, with post hoc Dunnett’s multiple comparison test. **G** One-way ANOVA test, $F(6, 50) = 3.461$, $p = 0.0061$, with post hoc Dunnett’s multiple comparison test. All post hoc Dunnett’s multiple comparison tests were performed with the vehicle group as control. All, except the group of (+TNF- α + IL-1 α , 100 ng/ml), $n = 8$ fields of 4 independent dishes from one time differentiations of two control healthy hiPSC lines each, n(+TNF- α + IL-1 α , 100 ng/ml) = 9 fields of 4 independent dishes from one time differentiations of two control healthy hiPSC lines each. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$, **** $p < 0.0001$




Fig. 5 Administration experiment of neutralizing antibodies of TNF- α and IL-1 α with TD-GM-CSF M Φ . **A** Summary of the administration experiment of neutralizing antibodies; the same protocol was used with ASD-GM-CSF M Φ . **B** Representative images at DIV56 of immunostaining of MAP2 + dendrite co-cultured with TD-GM-CSF M Φ and simultaneous administration of neutralizing antibodies for TNF- α , IL-1 α , or both, or corresponding isotype antibodies (IgG) at a concentration of 1 μ g/ml. All neurons were induced from 201B7 hiPSC line, and co-cultured with macrophages of TD4. Scale bar: 100 μ m. **C–G** Results of **(C)** total length of MAP2 + dendrite, **D** average length of MAP2 + dendrite, **E** max length of MAP2 + dendrite, **F** MAP2 + dendrite count, and **G** branch point count of MAP2 + dendrite. The shortening of MAP2 + dendrites observed in co-culture with TD-GM-CSF M Φ was prevented by the simultaneous administration of neutralizing antibodies. **C–F** One-way ANOVA test with post hoc Tukey’s multiple comparison test (**C**) $F(3, 142) = 6.606, p = 0.0003$, **D**) $F(3, 142) = 11.25, p < 0.0001$, **E**) $F(3, 142) = 13.05, p < 0.0001$, (**F**) $F(3, 142) = 1.544, p = 0.2058$. **G** Brown–Forsythe ANOVA test, $F(3.00, 127.0) = 1.759, p = 0.1584$, with post hoc multiple comparison test of Dunnett’s T3. $n(\text{TD-GM-CSF M}\Phi + \text{IgG}) = 35$ fields of 15 independent dishes from five times differentiations of two control healthy hiPSC lines each, $n(\text{TD-GM-CSF M}\Phi + \text{anti-IL-1}\alpha \text{ Ab}) = 38$ fields of 18 independent dishes from five times differentiations of two control healthy hiPSC lines each, $n(\text{TD-GM-CSF M}\Phi + \text{anti-TNF-}\alpha \text{ Ab}) = 37$ fields of 17 independent dishes from five times differentiations of two control healthy hiPSC lines each, and $n(\text{TD-GM-CSF M}\Phi + 2\text{Abs}) = 36$ fields of 16 independent dishes from five times differentiations of two control healthy hiPSC lines each. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$, **** $p < 0.0001$




Fig. 6 Administration experiment of neutralizing antibodies of TNF- α and IL-1 α with ASD-GM-CSF M Φ . **A** Representative images at DIV56 of immunostaining of MAP2 + dendrite co-cultured with ASD-GM-CSF M Φ and simultaneous administration of neutralizing antibodies for TNF- α , IL-1 α , or both, or the corresponding isotype antibodies (IgG) at a concentration of 1 μ g/ml. All neurons were induced from 201B7 hiPSC line, and co-cultured with macrophages of ASD1 were used in these images. Scale bar: 100 μ m. **B–F** Results of **(B)** total length of MAP2+ dendrite, **C** average length of MAP2+ dendrite, **D** max length of MAP2+ dendrite, **E** MAP2+ dendrite count, and **F** branch point count of MAP2+ dendrite. The shortening of MAP2+ dendrites observed in co-culture with ASD-GM-CSF M Φ was prevented by the simultaneous administration of neutralizing antibodies. **B** Brown–Forsythe ANOVA test, $F(3.00, 120.7) = 16.68, p < 0.0001$, with post hoc multiple comparison test of Dunnett’s T3. **C–D** One-way ANOVA test with post hoc Tukey’s multiple comparison test (**C**) $F(3, 139) = 9.166, p < 0.0001$, **D** $F(3, 139) = 0.2045, p = 0.8931$. **F** Brown–Forsythe ANOVA test, $F(3.00, 127.6) = 10.12, p < 0.0001$, with post hoc multiple comparison test of Dunnett’s T3. $n(\text{ASD-GM-CSF M}\Phi + \text{IgG}) = 33$ fields of 13 independent dishes from five times differentiations of two control healthy hiPSC lines each, $n(\text{ASD-GM-CSF M}\Phi + \text{anti-IL-1}\alpha \text{ Ab}) = 36$ fields of 16 independent dishes from five times differentiations of two control healthy hiPSC lines each, $n(\text{ASD-GM-CSF M}\Phi + \text{anti-TNF-}\alpha \text{ Ab}) = 36$ fields of 16 independent dishes from five times differentiations of two control healthy hiPSC lines each, and $n(\text{ASD-GM-CSF M}\Phi + 2\text{Abs}) = 38$ fields of 16 independent dishes from five times differentiations of two control healthy hiPSC lines each. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$, **** $p < 0.0001$

synaptic density [45]. A previous study analyzing IFN- γ effects on human neurons have shown that IFN- γ led to increased neurite outgrowth in hiPSC-derived neurons and concluded that the phenotype is similar to that observed in hiPSC neurons from individuals with ASD [41]. Although these results seem contradictory, ASD is a heterogeneous disorder [46], and its underlying pathology is unlikely to be homogeneous. Thus, a variety of

pathologies may be identified, especially in studies with small sample sizes like our study.

TNF- α is known to modulate brain development and function. Although TNF- α is released from various types of cells, including monocytes, T cells, mast cells, natural killer cells, keratinocytes, fibroblasts, and neurons, it is predominantly released from macrophages and microglia [47, 48]. In the CNS, TNF- α signaling has been shown

to exert several essential functions, including in neurogenesis, synaptic plasticity and scaling, injury-mediated activation of microglia and astrocytes, and the regulation of BBB permeability [49–52]; as such, abnormalities in TNF- α signaling can contribute to the onset of neuropsychiatric disorders, including ASD. In fact, the expression of TNF- α in the plasma, cerebrospinal fluid, and postmortem brain samples is higher in individuals with ASD than in TD individuals [53–55]. Our group has also reported elevated TNF- α levels in blood samples, lymphoblastoid cell lines, and macrophages of individuals with ASD [27, 32, 46]. However, only a limited number of studies have directly tested the effects of TNF- α using human neural progenitor cells or neurons, and the results were controversial. In the ischemic model, TNF- α protected neural progenitor cells to survive [56], whereas TNF- α disrupted brain organoid development of schizophrenia patients [57]; the combination treatment of TNF- α with IL-17A led to neurite disturbances in multiple sclerosis patient iPSC-derived neurons, while single cytokine treatment did not [58]. Although background pathologies and TNF- α concentrations vary, our result provided new insight into the detrimental potential of TNF- α , by itself, to inhibit dendritic outgrowth in human neurons. This finding is also supported by the fact that the effect of macrophages on MAP2+ dendrites is parallel to the TNF- α expression ratio of GM-CSF M Φ /M-CSF M Φ evident in our previous study. This included the differences between the TD and ASD.

The IL-1 family constitutes 11 cytokines and ten receptors, the former being divided into three subfamilies [59, 60]. IL-1 is a subfamily of pro-inflammatory cytokines secreted by diverse cells, including immune cells such as macrophages and monocyte [61]. Although IL-1 α and IL-1 β bind to the same receptor and trigger the same signal transduction, only IL-1 α is active in a precursor state and acts as an integral membrane protein, especially in macrophages [60, 62]. IL-1 has been shown to modulate neuronal signaling in homeostasis, such as sleep and memory formation, and in diseases, such as chronic fatigue, depression, anxiety and panic disorder, possibly in a concentration-dependent manner [63]. Most of the studies have analyzed IL-1 β , and less is known about IL-1 α . Human studies have reported that an association between the genetic mutation of IL-1 receptor accessory protein like 1 with learning disabilities and autism-like syndromes [64], and that IL-1 α promotes neurogenesis in adult human mesenchymal stem cells [65]; however, the direct effect of IL-1 α on brain cells remains to be elucidated. Our results likewise suggested such a new insight into IL-1 α action, showing that it can directly affect neurons and has the potential to alter dendrites. Interestingly, concerning the CNS, it has been reported that

IL-1 α and IL-1 β , in combination with TNF- α secreted from microglia, induce different types of astrocytes, neurotoxic and protective, respectively [42]. This additive effect of microglia-derived TNF- α and IL-1 α on astrocytes may cause the neuronal and behavioral changes shown in the rodent model [29]; however, this effect is not expected to exist in our culture model, which does not include astrocytes.

A recent study on amyotrophic lateral sclerosis (ALS) showed the therapeutic value of peripheral macrophages [66]. In this mouse model study, modifying macrophages at the periphery could suppress pro-inflammatory microglial responses, shift microglial activity to protect neuronal survival, and prevent disease progression. In addition, it is known that during certain diseases or injuries, such as ischemic stroke, traumatic brain injury, and neurodegenerative diseases, peripherally derived macrophages may infiltrate the brain where they show an M1-microglia like phenotype [67–69]; however, in this ALS model, peripheral macrophages do not enter the brain. Whether or not this hypothesis applies to ASD remains to be elucidated, but these results indicate the possibility of treating ASD simply by modifying peripheral macrophages with the peripheral administration of neutralizing cytokine antibodies, as partially shown here. Fortunately, some neutralizing antibodies against IL-1 α and TNF- α are already in practical use for treating cancers, rheumatoid arthritis, and other chronic local inflammatory diseases [70, 71]. Future research on accumulated evidence from human ASD trials is expected.

Limitations

One of the limitations of the present study was the small sample size with a gender bias toward males; it is therefore unclear whether the results also apply to a more diverse general population. Second, the condition of the cell culture model was far from the *in vivo* brain environment in the absence of GABAergic inhibitory neurons and glial cells, especially astrocytes, and macrophages were artificially polarized by GM-CSF or M-CSF to either end of its spectrum of phenotype [72]. Furthermore, it has been shown that these can rapidly switch from one phenotype to another, *in vivo* [73, 74]. It has not been directly analyzed whether the high expression of inflammatory cytokines in GM-CSF M Φ and the differences between TD and ASD were maintained under co-culture conditions. Additionally, neurons were derived from two healthy control subjects; thus, we could not analyze the interaction effect of neurons and macrophages in individuals with ASD. However, using such simplified culture systems, we could identify macrophage abnormalities in ASD.

Conclusions

In conclusion, our co-culture system revealed the adverse effects of the GM-CSF M Φ of individuals with ASD on neuronal dendrites via the secretion of the pro-inflammatory cytokines, IL-1 α and TNF- α . These results will be useful for understanding the pathobiology of ASD and for future drug discovery.

Abbreviations

ASD	Autism spectrum disorder
CNS	Central nervous system
PBMCs	Peripheral blood mononuclear cells
BBB	Blood–brain barrier
IFN- γ	Interferon- γ
IL	Interleukin
CAMs	CNS-associated macrophages
TNF- α	Tumor necrosis factor- α
GM-CSF M Φ	Granulocyte–macrophage colony-stimulating factor-induced macrophages
M-CSF M Φ	Macrophage colony-stimulating factor-induced macrophages
TD	Typically developed
mPFC	Medial prefrontal cortex
hiPSC	Human iPSC cell
ADOS-2	Autism Diagnostic Observation Schedule-2
AQ-J	Autism Quotient–Japanese version
FIQ	Full intelligence quotient
qRT-PCR	Quantitative reverse transcription–polymerase chain reaction
DIV	Day in vitro
ICC	Immunocytochemistry
PBS	Phosphate-buffered saline
MAP2	Microtubule-associated protein 2
ANOVA	Analysis of variance
HSD	Honest significant test
Tuj-1	Beta III tubulin
vGlut2	Vesicular glutamate transporter 2
IFN- γ	Interferon- γ
ALS	Amyotrophic lateral sclerosis

Supplementary Information

The online version contains supplementary material available at <https://doi.org/10.1186/s13229-024-00589-2>.

Additional file 1. Supplementary methods and figures.

Acknowledgements

We would like to thank Editage (www.editage.com) for English language editing.

Author contributions

R.T., M.T., H.O., and M.M. designed the study and drafted the manuscript. R.T., M.T., T.Y., R.I., Y.K., M.Ikehara, Y.Noriyama, and K.K. recruited and characterized the participants. R.T., M.T., Y.Nishi, and M.Ishikawa generated control iPSC-derived neurons and macrophages from participants. R.T., M.T., K.Y., T.K., and Y.Nishi designed and performed the biochemical analysis. K.Y., M.Ikehara, and Y.S. performed the electrophysiological analysis. All authors read and approved the final manuscript.

Funding

This work was supported by Grants-in-Aid for Scientific Research, KAKENHI 16K10191, 19K08025 (M.T.), 23K07018 (T.Y.), 23H04173 (M.M.), from the Japan Society for the Promotion of Science (JSPS), Japan Agency for Medical Research and Development (AMED) under Grant Number 21wm04250XXs0101, 21uk1024002h0002 (M.M.), 22bm0804023h0003 (M.I.), AMED-PRIME under Grant Number 21gm6310015h0002 (M.M.), AMED-CREST under Grant Number 22gm1510009h0001, 23gm1910004s0301 (M.M.), and

the Takeda Science Foundation (M.T.). The funding sources were not involved in the study design, collection, analysis, or interpretation of the data, manuscript preparation, or in the decision to submit the article for publication.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Declarations

Ethics approval and consent to participate

This study was approved by the appropriate ethics committees of Nara Medical University. It was conducted by the Code of Ethics of the World Medical Association (Declaration of Helsinki) for the experiments involving humans. All participants were given a complete description of the study and provided written informed consent before enrollment.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Author details

¹Department of Psychiatry, Nara Medical University School of Medicine, 840 Shijo-Cho, Kashihara City, Nara 634-8522, Japan. ²Department of Physiology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-Ku, Tokyo 160-8582, Japan. ³Department of Neurophysiology, Nara Medical University School of Medicine, 840 Shijo-Cho, Kashihara City, Nara 634-8522, Japan. ⁴Osaka Psychiatric Research Center, 3-16-21 Miyanosaka, Hirakata City, Osaka, 573-0022, Japan.

Received: 16 February 2023 Accepted: 6 February 2024

Published online: 21 February 2024

References

- Gyawali S, Patra BN. Autism spectrum disorder: trends in research exploring etiopathogenesis. *Psychiatry Clin Neurosci*. 2019;73(8):466–75.
- Lai M-C, Lombardo MV, Baron-Cohen S. Autism. *The Lancet*. 2014;383(9920):896–910.
- Lord C, Brugha TS, Charman T, Cusack J, Dumas G, Frazier T, et al. Autism spectrum disorder. *Nat Rev Dis Primers*. 2020;6(1):5.
- Meltzer A, Van de Water J. The role of the immune system in autism spectrum disorder. *Neuropsychopharmacology*. 2017;42(1):284–98.
- Gottfried C, Bambini-Junior V, Francis F, Riesgo R, Savino W. The impact of neuroimmune alterations in autism spectrum disorder. *Front Psychiatry*. 2015;6:121.
- Modabbernia A, Velthorst E, Reichenberg A. Environmental risk factors for autism: an evidence-based review of systematic reviews and meta-analyses. *Mol Autism*. 2017;8:13.
- Estes ML, McAllister AK. Immune mediators in the brain and peripheral tissues in autism spectrum disorder. *Nat Rev Neurosci*. 2015;16(8):469–86.
- Xu G, Snetselaar LG, Jing J, Liu B, Strathearn L, Bao W. Association of food allergy and other allergic conditions with autism spectrum disorder in children. *JAMA Netw Open*. 2018;1(2): e180279.
- Zerbo O, Leong A, Barcellos L, Bernal P, Fireman B, Croen LA. Immune mediated conditions in autism spectrum disorders. *Brain Behav Immun*. 2015;46:232–6.
- Lee AS, Azmitia EC, Whitaker-Azmitia PM. Developmental microglial priming in postmortem autism spectrum disorder temporal cortex. *Brain Behav Immun*. 2017;62:193–202.
- Gandal MJ, Zhang P, Hadjimiichael E, Walker RL, Chen C, Liu S, et al. Transcriptome-wide isoform-level dysregulation in ASD, schizophrenia, and bipolar disorder. *Science*. 2018;362(6420):eaat8127.

12. Velmeshev D, Schirmer L, Jung D, Hauessler M, Perez Y, Mayer S, et al. Single-cell genomics identifies cell type-specific molecular changes in autism. *Science*. 2019;364(6441):685–9.
13. Siniscalco D, Schultz S, Brigida AL, Antonucci N. Inflammation and neuro-immune dysregulations in autism spectrum disorders. *Pharmaceuticals* (Basel). 2018;11(2):56.
14. Masi A, Glozier N, Dale R, Guastella AJ. The immune system, cytokines, and biomarkers in autism spectrum disorder. *Neurosci Bull*. 2017;33(2):194–204.
15. Lin CW, Septyaningtrias DE, Chao HW, Konda M, Atarashi K, Takeshita K, et al. A common epigenetic mechanism across different cellular origins underlies systemic immune dysregulation in an idiopathic autism mouse model. *Mol Psychiatry*. 2022.
16. Banks WA. Blood-brain barrier transport of cytokines: a mechanism for neuropathology. *Curr Pharm Des*. 2005;11(8):973–84.
17. Cheng Y, Desse S, Martinez A, Worthen RJ, Jope RS, Beurel E. TNF α disrupts blood brain barrier integrity to maintain prolonged depressive-like behavior in mice. *Brain Behav Immun*. 2018;69:556–67.
18. Fiorentino M, Sapone A, Senger S, Camhi SS, Kadzielski SM, Buie TM, et al. Blood-brain barrier and intestinal epithelial barrier alterations in autism spectrum disorders. *Mol Autism*. 2016;7:49.
19. Corraliza I. Recruiting specialized macrophages across the borders to restore brain functions. *Front Cell Neurosci*. 2014;8:262.
20. Varatharaj A, Galea I. The blood-brain barrier in systemic inflammation. *Brain Behav Immun*. 2017;60:1–12.
21. McKim DB, Weber MD, Niraula A, Sawicki CM, Liu X, Jarrett BL, et al. Microglial recruitment of IL-1 β -producing monocytes to brain endothelium causes stress-induced anxiety. *Mol Psychiatry*. 2018;23(6):1421–31.
22. Da Mesquita S, Fu Z, Kipnis J. The meningeal lymphatic system: a new player in neurophysiology. *Neuron*. 2018;100(2):375–88.
23. Li Q, Barres BA. Microglia and macrophages in brain homeostasis and disease. *Nat Rev Immunol*. 2018;18(4):225–42.
24. Masuda T, Amann L, Monaco G, Sankowski R, Staszewski O, Krueger M, et al. Specification of CNS macrophage subsets occurs postnatally in defined niches. *Nature*. 2022;604(7907):740–8.
25. Paolicelli RC, Sierra A, Stevens B, Tremblay ME, Aguzzi A, Ajami B, et al. Microglia states and nomenclature: a field at its crossroads. *Neuron*. 2022;110(21):3458–83.
26. Park MD, Silvén A, Ginhoux F, Merad M. Macrophages in health and disease. (1097–4172 (Electronic)).
27. Yamauchi T, Makinodan M, Toritsuka M, Okumura K, Kayashima Y, Ishida R, et al. Tumor necrosis factor- α expression aberration of M1/M2 macrophages in adult high-functioning autism spectrum disorder. *Autism Res*. 2021;14(11):2330–41.
28. McEwen BS, Morrison JH. The brain on stress: vulnerability and plasticity of the prefrontal cortex over the life course. *Neuron*. 2013;79(1):16–29.
29. Nie X, Kitaoka S, Tanaka K, Segi-Nishida E, Imoto Y, Ogawa A, et al. The innate immune receptors TLR2/4 mediate repeated social defeat stress-induced social avoidance through prefrontal microglial activation. *Neuron*. 2018;99(3):464–79e7.
30. Katsuki R, Tateno M, Kubo H, Kurahara K, Hayakawa K, Kuwano N, et al. Autism spectrum conditions in hikikomori: A pilot case-control study. *Psychiatry Clin Neurosci*. 2020;74(12):652–8.
31. Gillott A, Standen PJ. Levels of anxiety and sources of stress in adults with autism. *J Intellect Disabil*. 2007;11(4):359–70.
32. Makinodan M, Iwata K, Ikawa D, Yamashita Y, Yamamuro K, Toritsuka M, et al. Tumor necrosis factor- α expression in peripheral blood mononuclear cells correlates with early childhood social interaction in autism spectrum disorder. *Neurochem Int*. 2017;104:1–5.
33. Lord C, Rutter M, Goode S, Heemsbergen J, Jordan H, Mawhood L, et al. Autism diagnostic observation schedule: a standardized observation of communicative and social behavior. *J Autism Dev Disord*. 1989;19(2):185–212.
34. Baron-Cohen S, Wheelwright S, Skinner R, Martin J, Clubley E. The autism-spectrum quotient (AQ): evidence from Asperger syndrome/high-functioning autism, males and females, scientists and mathematicians. *J Autism Dev Disord*. 2001;31(1):5–17.
35. Kurita H, Koyama T, Osada H. Autism-Spectrum Quotient-Japanese version and its short forms for screening normally intelligent persons with pervasive developmental disorders. *Psychiatry Clin Neurosci*. 2005;59(4):490–6.
36. Sumiyoshi C, Fujino H, Sumiyoshi T, Yasuda Y, Yamamori H, Ohi K, et al. Usefulness of the Wechsler Intelligence Scale short form for assessing functional outcomes in patients with schizophrenia. *Psychiatry Res*. 2016;245:371–8.
37. Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. *Cell*. 2007;131(5):861–72.
38. Toritsuka M, Yoshino H, Makinodan M, Ikawa D, Kimoto S, Yamamuro K, et al. Developmental dysregulation of excitatory-to-inhibitory GABA-polarity switch may underlie schizophrenia pathology: a monozygotic-twin discordant case analysis in human iPSC cell-derived neurons. *Neurochem Int*. 2021;150: 105179.
39. Ishii T, Ishikawa M, Fujimori K, Maeda T, Kushima I, Arioka Y, et al. In vitro modeling of the bipolar disorder and schizophrenia using patient-derived induced pluripotent stem cells with copy number variations of PCDH15 and RELN. *eNeuro*. 2019;6(5).
40. Matelski L, Morgan RK, Grodzki AC, Van de Water J, Lein PJ. Effects of cytokines on nuclear factor- κ B, cell viability, and synaptic connectivity in a human neuronal cell line. *Mol Psychiatry*. 2021;26(3):875–87.
41. Warre-Cornish K, Perfect L, Nagy R, Duarte RRR, Reid MJ, Raval P, et al. Interferon- γ signaling in human iPSC-derived neurons recapitulates neurodevelopmental disorder phenotypes. *Sci Adv*. 2020;6(34):eaay9506.
42. Liddelow SA, Guttenplan KA, Clarke LE, Bennett FC, Bohlen CJ, Schirmer L, et al. Neurotoxic reactive astrocytes are induced by activated microglia. *Nature*. 2017;541(7638):481–7.
43. Just MA, Keller TA, Malave VL, Kana RK, Varma S. Autism as a neural systems disorder: a theory of frontal-posterior underconnectivity. *Neurosci Biobehav Rev*. 2012;36(4):1292–313.
44. Mukaetova-Ladinska EB, Arnold H, Jaros E, Perry R, Perry E. Depletion of MAP2 expression and laminar cytoarchitectonic changes in dorsolateral prefrontal cortex in adult autistic individuals. *Neuropathol Appl Neurobiol*. 2004;30(6):615–23.
45. Deshpande A, Yadav S, Dao DQ, Wu ZY, Hokanson KC, Cahill MK, et al. Cellular phenotypes in human iPSC-derived neurons from a genetic model of autism spectrum disorder. *Cell Rep*. 2017;21(10):2678–87.
46. Yamashita Y, Makinodan M, Toritsuka M, Yamauchi T, Ikawa D, Kimoto S, et al. Anti-inflammatory effect of ghrelin in lymphoblastoid cell lines from children with autism spectrum disorder. *Front Psychiatry*. 2019;10:152.
47. Gregersen R, Lambertsen K, Finsen B. Microglia and macrophages are the major source of tumor necrosis factor in permanent middle cerebral artery occlusion in mice. *J Cereb Blood Flow Metab*. 2000;20(1):53–65.
48. Tracey D, Klareskog L, Sasso EH, Salfeld JG, Tak PP. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. *Pharmacol Ther*. 2008;117(2):244–79.
49. McCoy MK, Tansey MG. TNF signaling inhibition in the CNS: implications for normal brain function and neurodegenerative disease. *J Neuroinflammation*. 2008;5:45.
50. Bradley JR. TNF-mediated inflammatory disease. *J Pathol*. 2008;214(2):149–60.
51. Probert L. TNF and its receptors in the CNS: The essential, the desirable and the deleterious effects. *Neuroscience*. 2015;302:2–22.
52. Stellwagen D, Malenka RC. Synaptic scaling mediated by glial TNF- α . *Nature*. 2006;440(7087):1054–9.
53. Ricci S, Businaro R, Ippoliti F, Lo Vasco VR, Massoni F, Onofri E, et al. Altered cytokine and BDNF levels in autism spectrum disorder. *Neurotox Res*. 2013;24(4):491–501.
54. Chez MG, Dowling T, Patel PB, Khanna P, Kominsky M. Elevation of tumor necrosis factor- α in cerebrospinal fluid of autistic children. *Pediatr Neurol*. 2007;36(6):361–5.
55. Li X, Chauhan A, Sheikh AM, Patil S, Chauhan V, Li XM, et al. Elevated immune response in the brain of autistic patients. *J Neuroimmunol*. 2009;207(1–2):111–6.
56. Kim M, Jung K, Kim IS, Lee IS, Ko Y, Shin JE, et al. TNF- α induces human neural progenitor cell survival after oxygen-glucose deprivation by activating the NF- κ B pathway. *Exp Mol Med*. 2018;50(4):1–14.
57. Benson CA, Powell HR, Liput M, Dinham S, Freedman DA, Ignatowski TA, et al. Immune factor, TNF α , disrupts human brain organoid development similar to schizophrenia-schizophrenia increases developmental vulnerability to TNF α . *Front Cell Neurosci*. 2020;14:233.
58. Kerkering J, Muinjonov B, Rosiewicz KS, Diecke S, Biese C, Schiweck J, et al. iPSC-derived reactive astrocytes from patients with multiple sclerosis

- protect cocultured neurons in inflammatory conditions. *J Clin Invest.* 2023;133(13).
59. Dinarello CA. Overview of the IL-1 family in innate inflammation and acquired immunity. *Immunol Rev.* 2018;281(1):8–27.
 60. Mantovani A, Dinarello CA, Molgora M, Garlanda C. Interleukin-1 and related cytokines in the regulation of inflammation and immunity. *Immunity.* 2019;50(4):778–95.
 61. Gabay C, Lamacchia C, Palmer G. IL-1 pathways in inflammation and human diseases. *Nat Rev Rheumatol.* 2010;6(4):232–41.
 62. Migliorini P, Italiani P, Pratesi F, Puxeddu I, Boraschi D. The IL-1 family cytokines and receptors in autoimmune diseases. *Autoimmun Rev.* 2020;19(9): 102617.
 63. Nemeth DP, Quan N. Modulation of neural networks by interleukin-1. *Brain Plast.* 2021;7(1):17–32.
 64. Ramos-Brossier M, Montani C, Lebrun N, Gritti L, Martin C, Seminatore-Nole C, et al. Novel IL1RAPL1 mutations associated with intellectual disability impair synaptogenesis. *Hum Mol Genet.* 2015;24(4):1106–18.
 65. Greco SJ, Rameshwar P. Enhancing effect of IL-1alpha on neurogenesis from adult human mesenchymal stem cells: implication for inflammatory mediators in regenerative medicine. *J Immunol.* 2007;179(5):3342–50.
 66. Chiot A, Zaidi S, Iltis C, Ribon M, Berriat F, Schiaffino L, et al. Modifying macrophages at the periphery has the capacity to change microglial reactivity and to extend ALS survival. *Nat Neurosci.* 2020;23(11):1339–51.
 67. Sandoval KE, Witt KA. Blood-brain barrier tight junction permeability and ischemic stroke. *Neurobiol Dis.* 2008;32(2):200–19.
 68. Alves JL. Blood-brain barrier and traumatic brain injury. *J Neurosci Res.* 2014;92(2):141–7.
 69. Bennett J, Basivireddy J, Kollar A, Biron KE, Reickmann P, Jefferies WA, et al. Blood-brain barrier disruption and enhanced vascular permeability in the multiple sclerosis model EAE. *J Neuroimmunol.* 2010;229(1–2):180–91.
 70. Monaco C, Nanchahal J, Taylor P, Feldmann M. Anti-TNF therapy: past, present and future. *Int Immunol.* 2015;27(1):55–62.
 71. Cavalli G, Colafrancesco S, Emmi G, Imazio M, Lopalco G, Maggio MC, et al. Interleukin 1alpha: a comprehensive review on the role of IL-1alpha in the pathogenesis and treatment of autoimmune and inflammatory diseases. *Autoimmun Rev.* 2021;20(3): 102763.
 72. Mills CD. Anatomy of a discovery: m1 and m2 macrophages. *Front Immunol.* 2015;6:212.
 73. Wang N, Liang H, Zen K. Molecular mechanisms that influence the macrophage m1–m2 polarization balance. *Front Immunol.* 2014;5:614.
 74. Shapouri-Moghaddam A, Mohammadian S, Vazini H, Taghadosi M, Esmaeili SA, Mardani F, et al. Macrophage plasticity, polarization, and function in health and disease. *J Cell Physiol.* 2018;233(9):6425–40.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.